Artwork

Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Addressing Treatment Gaps Among Patients with MDS-Associated Anemia

 
Share
 

Manage episode 424756769 series 1103955
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jamie Koprivnikar, MD
Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for this patient population. Tune in to learn more about evaluating patients with MDS, the potential of Reblozyl, and where it fits into the treatment landscape with Dr. Charles Turck as he takes a deep dive with Dr. Jamie Koprivnikar, MD, Hematologist, Oncologist, at Hackensack Meridian Health.

REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.
REBLOZYL® is licensed from Merck & Co. Inc., Rahway, NJ, USA and its affiliates.
© 2024 Bristol-Myers Squibb Company
2007-US-2300376 03/24

  continue reading

43 episodes

Artwork
iconShare
 
Manage episode 424756769 series 1103955
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jamie Koprivnikar, MD
Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for this patient population. Tune in to learn more about evaluating patients with MDS, the potential of Reblozyl, and where it fits into the treatment landscape with Dr. Charles Turck as he takes a deep dive with Dr. Jamie Koprivnikar, MD, Hematologist, Oncologist, at Hackensack Meridian Health.

REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.
REBLOZYL® is licensed from Merck & Co. Inc., Rahway, NJ, USA and its affiliates.
© 2024 Bristol-Myers Squibb Company
2007-US-2300376 03/24

  continue reading

43 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide